文献速递乳腺技术与安全MR

COVID-19加强针接种前后乳腺MRI腋窝淋巴结对比

Comparison of Axillary Lymph Nodes on Breast MRI Before and After COVID-19 Booster Vaccination.
PubMed 文献 · Acad Radiol · 2023-03-16

本研究回顾性分析128例接种COVID-19加强针后行乳腺MRI的患者,比较接种后与初次接种前腋窝淋巴结皮质厚度。19%患者皮质厚度增加≥0.2 cm,且与接种后时间较短相关(中位9天 vs 36天,p<0.001),年龄和疫苗类型无关。结论认为加强针后腋窝淋巴结肿大常见,尤其3周内,低恶性风险者可省略额外评估。

要点

  • 乳腺MRI上接种同侧腋窝淋巴结皮质厚度增加≥0.2 cm者占19%。
  • 皮质增厚更常见于接种后3周内,中位时间9天。
  • 低恶性风险患者可避免不必要的活检或短期随访。

关键影像表现/征象

  • 皮质增厚组接种后中位时间9天(IQR 5,20),无增厚组36天(IQR 18,59),差异有统计学意义(p<0.001)。
  • 年龄(p=0.5)和疫苗类型(p=0.7)与皮质增厚无显著关联。
  • 随访未诊断同侧乳腺癌或恶性淋巴结病变。

诊断标准与关键数值

  • 以同侧腋窝淋巴结最大皮质厚度增加≥0.2 cm作为淋巴结肿大的判定标准。
  • 接种后中位9天(IQR 5,20)更易出现皮质增厚,无增厚组中位36天(IQR 18,59)。

临床应用与阅片要点

  • 阅片时注意询问COVID-19加强针接种史及接种侧别,避免将反应性淋巴结误判为转移。
  • 对接种后3周内出现的同侧腋窝淋巴结皮质增厚,若缺乏恶性征象,可建议随访而非立即活检。
  • 报告时应描述淋巴结皮质厚度、形态及有无脂肪门,结合接种时间综合判断。

局限性

  • 回顾性单中心设计,样本量有限。
  • 仅纳入接种加强针后行乳腺MRI的患者,可能存在选择偏倚。
  • 未报告淋巴结皮质厚度的具体测量者间一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Vaccine-related lymphadenopathy is a frequent finding following initial coronavirus disease 2019 (COVID-19) vaccination, but the frequency after COVID-19 booster vaccination is still unknown. In this study we compare axillary lymph node morphology on breast MRI before and after COVID-19 booster vaccination.

MATERIALS AND METHODS: This retrospective, single-center, IRB-approved study included patients who underwent breast MRI between October 2021 and December 2021 after the COVID-19 booster vaccination. The axillary lymph node with the greatest cortical thickness ipsilateral to the side of vaccination was measured on MRI after booster vaccination and before initial COVID-19 vaccination. Comparisons were made between patients with and without increase in cortical thickness of ≥ 0.2 cm. Continuous covariates were compared using Wilcoxon rank-sum test and categorical covariates were compared using Fisher's exact test. Multiple comparison adjustment was made using the Benjamini-Hochberg procedure.

RESULTS: All 128 patients were included. Twenty-four of 128 (19%) displayed an increase in lymph node cortical thickness of ≥ 0.2 cm. Patients who received the booster more recently were more likely to present cortical thickening, with a median of 9 days (IQR 5, 20) vs. 36 days (IQR 18, 59) (p < 0.001). Age (p = 0.5) and type of vaccine (p = 0.7) were not associated with thickening. No ipsilateral breast cancer or malignant lymphadenopathy were diagnosed on follow-up.

CONCLUSION: Axillary lymphadenopathy on breast MRI following COVID-19 booster vaccination is a frequent finding, especially in the first 3 weeks after vaccination. Additional evaluation or follow-up may be omitted in patients with low concern for malignancy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Parikh, Feigin, Sevilimedu, et al. Comparison of Axillary Lymph Nodes on Breast MRI Before and After COVID-19 Booster Vaccination. Acad Radiol. 2023. PMID: 37037711. doi:10.1016/j.acra.2023.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。